Codexis, Inc.  

(Public, NASDAQ:CDXS)   Watch this stock  
Find more results for cdxs
5.85
0.00 (0.00%)
After Hours: 5.85 0.00 (0.00%)
Sep 25, 4:40PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.70 - 5.90
52 week 3.60 - 5.97
Open 5.80
Vol / Avg. 98,417.00/188,850.00
Mkt cap 282.70M
P/E     -
Div/yield     -
EPS -0.41
Shares 48.32M
Beta -1.36
Inst. own 71%
Sep 11, 2017
Codexis Inc at Rodman & Renshaw Global Investment Conference
Sep 8, 2017
Codexis Inc at BioCentury NewsMakers in the Biotech Industry Conference
Aug 9, 2017
Q2 2017 Codexis Inc Earnings Call - Webcast
Aug 9, 2017
Q2 2017 Codexis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -60.69% -17.52%
Operating margin -61.24% -17.54%
EBITD margin - -11.78%
Return on average assets -62.65% -21.32%
Return on average equity -119.05% -40.77%
Employees 106 -
CDP Score - -

Address

200 Penobscot Dr
REDWOOD CITY, CA 94063-4718
United States - Map
+1-650-4218100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Officers and directors

Bernard J. Kelley Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
John J. Nicols President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Gordon T. Sangster Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Michael Douglas Arthur Aldridge Senior Vice President - Corporate & Strategic Development
Bio & Compensation  - Reuters
James Lalonde Senior Vice President, Research & Development
Age: 54
Bio & Compensation  - Reuters
Thomas R. Baruch J.D. Chairman Emeritus
Bio & Compensation  - Reuters
Pam P. Cheng Director
Age: 45
Bio & Compensation  - Reuters
Kathleen Sereda Glaub Director
Bio & Compensation  - Reuters
Patrick Y. Yang Director
Age: 69
Bio & Compensation  - Reuters